{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:09:18Z","timestamp":1791828558024,"version":"4.3.4"},"reference-count":49,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2007,4,30]],"date-time":"2007-04-30T00:00:00Z","timestamp":1177891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2007,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) are clinically and pathologically linked. Anti\u2013tumor necrosis factor (anti\u2010TNF) agents are efficacious in treating AS, but not all are equally effective in treating IBD (Crohn's disease [CD] and ulcerative colitis [UC]). The purpose our study was to analyze the incidence of flares and new onset of IBD in patients with AS treated with anti\u2010TNF agents.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data from 9 trials, 7 placebo\u2010controlled trials and 2 open studies, were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Data were available on 419 AS patients exposed to etanercept (625 patient\u2010years), 366 exposed to infliximab (618 patient\u2010years), 295 exposed to adalimumab (132 patient\u2010years), and 434 placebo patients (150 patient\u2010years). A history of IBD was reported in 76 of 1,130 patients (6.7%). There were 2 reports of IBD while receiving placebo (1.3 per 100 patient\u2010years), 1 while receiving infliximab, and 3 while receiving adalimumab. Among the 14 IBD cases receiving etanercept (2.2 per 100 patient\u2010years) there were 8 CD and 6 UC cases, significantly different from infliximab (<jats:italic>P<\/jats:italic> = 0.01) but not from placebo. Patients with a history of IBD had an IBD flare odds ratio of 18.0 (95% confidence interval [95% CI] 2\u2013154) while taking etanercept and 4.2 (95% CI 0.4\u201344) while taking adalimumab, in comparison with infliximab. The incidence rates of new onset of IBD showed no significant difference between etanercept (0.8 per 100 patient\u2010years) and placebo (0.5 per 100 patient\u2010years).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>New onset and flare of IBD are infrequent events in AS patients receiving anti\u2010TNF therapy. Infliximab (but not etanercept) largely prevents IBD activity. More data are required for adalimumab. The incidence of new onset of IBD was statistically not different from placebo for all anti\u2010TNF agents.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.22669","type":"journal-article","created":{"date-parts":[[2007,4,30]],"date-time":"2007-04-30T18:46:38Z","timestamp":1177958798000},"page":"639-647","source":"Crossref","is-referenced-by-count":162,"title":["Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti\u2013tumor necrosis factor \u03b1 agents"],"prefix":"10.1002","volume":"57","author":[{"given":"J.","family":"Braun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Baraliakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Listing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Haibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rudwaleit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sieper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,4,30]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380407"},{"key":"e_1_2_6_3_2","first-page":"696","article-title":"Primary ankylosing spondylitis, psoriatic and enteropathic spondyloarthropathy: a controlled analysis","volume":"18","author":"Edmunds L","year":"1991","journal-title":"J Rheumatol"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/PL00000223"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20977"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08215-6"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11104"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.025130"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh584"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20852"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11017"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh475"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11325"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20241"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.035105"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21563"},{"key":"e_1_2_6_17_2","first-page":"87","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: 102 week results of the ASSERT trial","volume":"65","author":"Braun J","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21913"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.28674"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70224-6"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"issue":"2","key":"e_1_2_6_22_2","first-page":"A105","article-title":"A randomized placebo\u2010controlled trial of infliximab for active ulcerative colitis: the ACT I trial","volume":"128","author":"Rutgeerts P","year":"2005","journal-title":"Gastroenterology"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.1.74"},{"key":"e_1_2_6_25_2","first-page":"752","article-title":"Development of Crohn's disease in a patient taking etanercept","volume":"32","author":"Oh J","year":"2005","journal-title":"J Rheumatol"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200309000-00007"},{"key":"e_1_2_6_27_2","first-page":"1605","article-title":"Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis","volume":"28","author":"Stone M","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012664"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.020875"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21197"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009735"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370105"},{"key":"e_1_2_6_33_2","first-page":"86","article-title":"The incidence of flares or new onsets of inflammatory bowel disease in patients with ankylosing spondylitis exposed to anti\u2010TNF\u03b1 therapy","volume":"65","author":"Braun J","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(05)00980-8"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.01944.x"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.305.6844.20"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.030"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21588"},{"key":"e_1_2_6_39_2","first-page":"1542","article-title":"Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study","volume":"18","author":"Mielants H","year":"1991","journal-title":"J Rheumatol"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-000-0006-z"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200105000-00002"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2005.01.006"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-H"},{"issue":"28","key":"e_1_2_6_44_2","first-page":"S38","article-title":"Influence of the gut and cytokine patterns in spondyloarthropathy","volume":"20","author":"Baeten D","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04954-0"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032268"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030409"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02530-7"},{"key":"e_1_2_6_49_2","first-page":"639","article-title":"Adalimumab is efficacious in treating skin disease in psoriatic arthritis: subanalysis by severity of psoriasis in ADEPT","volume":"65","author":"Gladman D","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_6_50_2","first-page":"211","article-title":"Adalimumab is efficacious in treating joint disease in early and established psoriatic arthritis: subanalysis of ADEPT","volume":"65","author":"Choy E","year":"2006","journal-title":"Ann Rheum Dis"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.22669","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.22669","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T10:17:28Z","timestamp":1700043448000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.22669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,30]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,5,15]]}},"alternative-id":["10.1002\/art.22669"],"URL":"https:\/\/doi.org\/10.1002\/art.22669","archive":["Portico"],"relation":{},"ISSN":["0893-7524","1529-0123"],"issn-type":[{"value":"0893-7524","type":"print"},{"value":"1529-0123","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4,30]]}}}